Epidemiology and prevention of meningococcal disease

Ramsay, 1997, Changing patterns of case ascertainment and trends in meningococcal disease in England and Wales, CDR Review, 7, R49 Noah, 1995 Riedo, 1995, Epidemiology and prevention of meningococcal disease, Pediatr Inf Dis J, 14, 643, 10.1097/00006454-199508000-00001 Greenwood, 1987, The epidemiology of acute bacterial meningitis in tropical Africa, 61 Moore, 1988, Group A meningococcal carriage in travellers returning from Saudi Arabia, JAMA, 260, 2686, 10.1001/jama.1988.03410180094036 Achtman, 1995, Global epidemiology of meningococcal disease Lassiter, 1992, Complement Factor 9 deficiency in the serum of neonates, J Infect Dis, 166, 53, 10.1093/infdis/166.1.53 Gold, 1978, Carriage of Neisseria meningitidis and Neisseria lactamica in infants and children, J Infect Dis, 137, 112, 10.1093/infdis/137.2.112 Caugant, 1994, Asymptomatic carriage of Neisseria meningitidis in a randomly sampled population, J Clin Microbiol, 32, 323, 10.1128/JCM.32.2.323-330.1994 Farrell, 1966, Nasopharyngeal carriers of Neisseria meningitidis. Studies among Air Force recruits, JAMA, 198, 1189, 10.1001/jama.1966.03110240097034 Stuart, 1989, Effect of smoking on meningococcal carriage, Lancet, 2, 723, 10.1016/S0140-6736(89)90781-2 Imrey, 1995, Meningococcal carriage, alcohol consumption and campus bar patronage in a serogroup C meningococcal disease outbreak, J Clin Microbiol, 33, 3133, 10.1128/JCM.33.12.3133-3137.1995 Griffiss, 1982, Epidemic meningococcal diseases: synthesis of a hypothetical immuno-epidemiological model, Rev Infect Dis, 4, 159, 10.1093/clinids/4.1.159 Griffiss, 1995, Mechanisms of host immunity Densen, 1991, Complement deficiencies and meningococcal disease, Clin and Exp Immunol, 86, 57 Super, 1989, Association of low levels of mannan binding protein with a common defect of opsonisation, Lancet, 335, 1236, 10.1016/S0140-6736(89)91849-7 Summerfield, 1997, Association of mutations in mannose binding protein gene with childhood infection in consecutive hospital series, BMJ, 314, 1229, 10.1136/bmj.314.7089.1229 Nadel, 1996, Variation in the tumour necrosis factor-alpha gene promoter region may be associated with death from meningococcal disease, J Infect Dis, 174, 878, 10.1093/infdis/174.4.878 Cartwright, 1995, Meningococcal carriage and disease Cartwright, 1991, Influenza A and meningococcal disease, Lancet, 338, 554, 10.1016/0140-6736(91)91112-8 De Vries, 1996, Invasion of primary nasopharyngeal cells by Neisseria meningitidis is controlled by phase variation of multiple surface antigens, Infect and Immun, 64, 2998, 10.1128/IAI.64.8.2998-3006.1996 Pearson, 1995, Antibiotic prophylaxis for bacterial meningitis: overuse and uncertain efficacy, J Pub Health Med, 17, 455 Cooke, 1989, Secondary cases of meningococcal infection among close family and household contacts in England and Wales, 1984–87, BMJ, 298, 555, 10.1136/bmj.298.6673.555 1995, Control of meningococcal disease: guidance for consultants in communicable disease control, CDR Review, 5, R189 1997, Management of clusters of meningococcal disease, CDR Review, 7, R3 Gottschlich, 1969, Human immunity to the meningococcus. V. The effect of immunisation with serogroup C polysaccharide on the carrier state, J Exp Med, 129, 1367, 10.1084/jem.129.6.1385 Finne, 1983, Antigenic similarities between brain components and bacteria causing meningitis, Lancet, 2, 355, 10.1016/S0140-6736(83)90340-9 Booy, 1994, Efficacy of Haemophilus influenzae type b conjugate vaccine PRP-T, Lancet, 344, 362, 10.1016/S0140-6736(94)91400-1 Beuvery, 1983, Preparation and immunochemical characterisation of meningococcal serogroup C polysaccharide-tetanus toxoid conjugates as a new generation of vaccines, Infect Immun, 40, 39, 10.1128/IAI.40.1.39-45.1983 Beuvery, 1983, Physiochemical and immunological characterisation of meningococcal serogroup A polysaccharide-tetanus toxoid conjugates prepared by two methods, Vaccine, 1, 31, 10.1016/0264-410X(83)90010-5 Moraes, 1992, Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil, Lancet, 340, 1074, 10.1016/0140-6736(92)93086-3 Boslego, 1995, Efficacy, safety and immunogenicity of a meningococcal group B outer membrane protein vaccine in Iquique, Chile, Vaccine, 13, 821, 10.1016/0264-410X(94)00037-N Frasch, 1995, Meningococcal vaccines past, present and future Gorringe, 1995, Human antibody response to meningococcal transferrin binding proteins: evidence for vaccine potential, Vaccine, 13, 1207, 10.1016/0264-410X(95)00055-6